Allotera Therapeutics: Series CDevelops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignanciesOct 4, 2026RoundOSAllotera TherapeuticsCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedBiotechUnited StatesNorth AmericaSeries C+